

Donald S Shepard, PhD
Email: shepard@brandeis.edu
The Heller School for Social Policy and
Management, Brandeis University
415 South Street, Waltham, MA 02453 USA

Impacts of age and season on rates of hospitalization for respiratory syncytial virus (RSV) in infants in the United States and their use of mechanical ventilation and charges



Donald S Shepard, PhD, FASTMH¹; Jennifer Perloff, PhD¹; Xiaohui Jiang, MS²; Mina Suh, MPH²; Jon Fryzek, PhD²; Diana Bowser, ScD, MPH¹; Christopher Rizzo, MD³; Christopher B Nelson, PhD, MPH³

¹The Heller School for Social Policy and Management, Brandeis University, 415 South Street, Waltham, MA 02453 USA; ²EpidStrategies, A Division of ToxStrategies, Inc., 9601 Medical Center Dr. Rockville, Maryland 20850 USA; ³Sanofi Pasteur, 1 Discovery Dr, Swiftwater, PA 18370 USA

Background

- Respiratory Syncytial Virus (RSV) infection is the leading cause of hospitalization in infants below age 12 months.
- Despite considerable evidence on the clinical predictors of RSV hospitalizations, little is known about their cost, its drivers and their relation to age and season.
- Specifically, the share of costs from infants at normal risk is unknown.
- Mechanical ventilation (MV) provides a well-documented marker of disease severity in hospitalizations.

Methods

Data source:

- The National Inpatient Sample was used to examine RSV inpatient admissions and their average charge from 2009 to 2011.¹
- This 3-year data set includes a large, nationally representative all-payer sample of 37,376 RSV admissions of infants in the US under age 12 months recorded by month.

Parameters calculated:

- Rate per 1000 infants of RSV hospitalizations (ICD-9-CM diagnosis codes 079.6, 466.11, 480.1)
- Share receiving MV (ICD-9-CM procedure codes 93.90, 96.01, 96.02, 96.03, 96.04, 96.05, 96.70, 96.71, 96.72)
- Mean charge per admission (separated by use of MV) with 95% confidence intervals (CI) by age and season, excluding incomplete data.

Analysis:

- All rates were converted to relative measures by dividing by the annual average (1.00 = annual average)
- All charges were adjusted to Jan 2020 based on the medical care component of the Consumer Price Index.
- Incomplete data were considered missing at random

Results

Hospitalization rates:


- Rates of hospitalization by age were highest for infants 1 month of chronological age (2.42 times the annual average) and declined steadily thereafter (Fig 1).
- The percentage of hospitalizations with MV averaged 4.5% (95% CI: 3.8%-5.2%).
- MV hospitalizations declined from months <1 to 5, with subsequent fluctuations through 11 months (Fig 1).


Hospitalization charges per episode:


- Charges varied relatively little by age.
- All-RSV charges exceeded the annual average only for infants aged <1 and 1 month (1.30 and 1.05 times the annual average, respectively, Fig 2).
- Average charges for all RSV differed little from RSV excluding MV because MV was relatively rare (4.87%).
- In 2020 prices, hospitalization charges per episode averaged \$175,211 with MV vs. \$17,313 without MV, totaling \$1.51 billion annually for the birth cohort of 4.04 million infants (\$374 per infant) (**Fig 2**).
- Average charges by month for all hospitalizations were similar to those excluding MV (Fig 3).


Use of MV:

- Hospitalizations without MV constituted 95.5% (95% CI 94.8%-96.2%) of all RSV hospitalizations and comprised 67.5% of aggregate yearly charges
- RSV hospitalizations are highly seasonal, peaking Jan-March (Fig 4).
- In every season, rates of RSV hospitalization and shares of hospitalization with MV are highest in infants aged 0-2 months and lowest in infants aged 9-11 months (Fig 5).










Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun

Month of the year



Conclusion

- Although MV hospitalization charges average 10 times higher, non-MV hospitalizations are 20 times more prevalent.
- Thus, infants with MV are <u>not</u> the main driver of RSV hospitalization charges.
- Due to their large share (95.5%) of RSV hospitalizations, those without MV constitute two-thirds of aggregate RSV inpatient charges.

References

1. HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2009-2011. Agency for Healthcare Research and Quality, Rockville, MD. https://doi.org/10.2009/nisoverview.jsp



